Numbers needed to vaccinate data

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adult Free full text available 3.4. Harm-benefit considerations In the Moderna trial, the excess risk of serious AESIs was 15.1 per 10,000 participant One in 662 (over placebo baselines) In the Pfizer trial, the excess risk of serious AESIs 10.1 per 10,000 One in 990 (over placebo baselines) Combined, mRNA vaccines, risk of serious adverse events of special interest 12.5 per 10,000 vaccinated One in 800 (over placebo baselines) 1,250 serious events for each million vaccine recipients Appendix 1: estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation, for primary vaccination, booster vaccination (3rd dose), autumn 2022 booster and,